Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.
about
Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysisImpact of 8-week linoleic acid intake in soy oil on Lp-PLA2 activity in healthy adults.Pharmacometabolomics reveals that serotonin is implicated in aspirin response variabilityClinical and laboratory factors associated with shear-dependent platelet hyper-reactivity in patients on chronic aspirin therapy.Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery.Tailored antiplatelet therapy and clinical adverse outcomes.Platelet content of nitric oxide synthase 3 phosphorylated at Serine 1177 is associated with the functional response of platelets to aspirin.Platelet function tests: a comparative review.Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspectiveMonitoring the effectiveness of antiplatelet therapy: opportunities and limitations.Acute coronary eventsInflammation and circulating endothelial progenitor cells in patients with coronary artery disease and residual platelet reactivityProtocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular diseasePrevalence of and risk factors for aspirin resistance in elderly patients with coronary artery diseaseCurrent concepts about inhibition of platelet aggregation.Contemporary platelet function testing.Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease.Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management.Assessment of oral antithrombotic therapy by platelet function testing.A contemporary viewpoint on 'aspirin resistance'.Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis.Monitoring aspirin and clopidogrel response: testing controversies and recommendations.Antiplatelet therapy: targeting the TxA2 pathway.Antiplatelet treatment in essential hypertension: where do we stand?Effect of cocoa products and flavanols on platelet aggregation in humans: a systematic review.New molecular insights into modulation of platelet reactivity in aspirin-treated patients using a network-based approach.Aspirin response: Differences in serum thromboxane B2 levels between clinical studies.Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications.Cross validation of aspirin effect in healthy individuals by Impact-R and PFA-100: a double blind randomized placebo controlled trial.A patient with HIV and tuberculosis with diminished clopidogrel response.Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia.Decreased Threshold of Aggregation to Low-Dose Epinephrine is Evidence of Platelet Hyperaggregability in Patients with Thrombosis.Stroke and aspirin non-responder patients: relation with hypertension and platelet response to adenosine diphosphate.Effects of uncoupling protein 2 -866G/A polymorphism on platelet reactivity and prognosis in Chinese patients with type 2 diabetes and ischemic stroke.Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.Association between sympathetic response, neurogenic cardiomyopathy, and venous thromboembolization in patients with primary subarachnoid hemorrhage.Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: Implications of more simple and useful test than platelet function testing.Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosisThe prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease
P2860
Q27010236-DD01EC6F-81DA-4C89-B62D-CCDEDBD2F223Q33651282-9B41FB15-6866-4E23-B1E2-A3A71887B560Q33994559-9857D95C-DBBC-4967-AD29-AAEA3E73255DQ34288732-85CF03F2-DF13-42D3-95D2-E5D258C0EDD8Q34952522-3397F457-438E-4A15-B59D-D8C010DD86AAQ35032042-E7ABF555-76C2-4B65-A4D3-874EF97085AAQ35077628-6589C59F-8F1A-4773-BDAD-B7D3E41B71ECQ35121464-37F6110B-BBC6-46D9-92D3-8A287E83D10DQ35174193-F8E6397C-9AEE-45CA-8EBF-13983899219EQ35373683-9EF3EFC4-FE15-4AB8-AC0F-6F7FC17D1726Q35878289-4344D1C7-14EE-4774-9770-B4FA0DAA3CFEQ36223037-26D54F3A-6E77-4052-BAB7-631CF6A30294Q36693620-1AF97600-6213-4D3E-9FA1-BAD6DA85F12CQ36769860-23A050AE-89ED-440D-89C2-15C853E0F9E4Q37326634-1FF262EE-14BD-46E6-A42A-7BBCB7B7B287Q37690764-645F519E-9BBC-4013-9198-F209249F8101Q37749813-FD5BBB11-950B-42F3-AFD4-DBD14EBFEDD8Q37809122-0995339A-4C1C-489B-8C95-F2767829D669Q37902507-D0CB2395-3F35-4AB1-9965-4988189914ABQ37989558-47E1593D-A446-4EBD-91F2-F851279BB628Q38023512-26B64A7F-D66D-4999-9B07-BF8017C06D82Q38099235-D05F8FCF-DDF5-4E61-BADB-82D9ABB7EEA1Q38172461-963677E7-1C45-4EB9-97BB-2CC908362E05Q38384163-84BC6DBE-1853-4A49-870A-2442BD741641Q38514821-075A10EA-D0E6-4DB2-A192-914654283926Q39992304-2D7C730D-E0F4-4D88-8A78-4DB4BD2CBD13Q41485945-85A6A061-ACA7-4E8A-B4EC-3C83D2379EFEQ41574497-0C5C77C2-EC25-418B-9E74-68A70007BE6CQ42167771-5223E413-40F9-43C3-A193-25B799B7625EQ42236259-5468D7BE-AA29-4302-8A9B-7DCB78E21E35Q42667008-1BFAA3FA-F71E-419B-A772-027C97EBD282Q42941261-B5C6A2B8-295B-4870-99B9-72218A792F2AQ43255962-3855E852-05EA-4695-A2AC-371515EA7F91Q44779179-572D7326-40A4-4F87-A0C1-E4D69C163BCDQ45145788-70C280C4-6A44-4B01-BEAE-71F91A35AE45Q45260109-4929ABFE-5B94-49FB-A5F4-238295FE45D1Q45698262-B93193BF-BEF9-4057-8007-95873EF2510AQ51026024-89E2DF3C-1BE8-4A8D-A10B-5FD2AB577151Q57734957-EF9EC945-5196-45E4-996E-6F1B2796481AQ58260743-7E12FB33-B6E8-4F17-A0B7-F93211BC1E85
P2860
Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of the PFA-100 closure tim ...... atic review and meta-analysis.
@en
Use of the PFA-100 closure tim ...... atic review and meta-analysis.
@nl
type
label
Use of the PFA-100 closure tim ...... atic review and meta-analysis.
@en
Use of the PFA-100 closure tim ...... atic review and meta-analysis.
@nl
prefLabel
Use of the PFA-100 closure tim ...... atic review and meta-analysis.
@en
Use of the PFA-100 closure tim ...... atic review and meta-analysis.
@nl
P2860
P921
P1476
Use of the PFA-100 closure tim ...... matic review and meta-analysis
@en
P2093
P De Moerloose
P2860
P304
P356
10.1111/J.1538-7836.2008.02897.X
P577
2008-01-10T00:00:00Z